Toggle menu

EMBOL1 Study

Start date:
Oct 2019
End date:
Oct 2020
Co-ordinated by:
LUMIRADx
Main trial site:
Manchester Royal Infirmary

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). It is the third most frequent cardiovascular disease with an overall annual incidence of
100–200 per 100 000 inhabitants. VTE may be lethal in the acute phase or lead to chronic disease and disability, but it is also often preventable. This study aims to assess the precision and accuracy of the LumiraDx point of Care (POC) D Dimer test when used in patients presenting with symptoms of VTE which can deliver a quantitative result in under 10 minutes from a finger stick blood sample. Current tests require venous blood samples or are laboratory tests that take 30-60+ minutes to return a result to the attending clinician.

Primary Objective: To determine the performance of the LumiraDx POC D Dimer assay when compared to the VIDAS D-Dimer Exclusion reference method in patients with suspected VTE.

Secondary objectives:

  1. Performance evaluation of the haematocrit measurement by the LumiraDx POC D Dimer test with Hemocue Hb 201 system.
  2. Clinical performance of the LumiraDx POC D Dimer assay when used as an aid in the exclusion of DVT and PE.

Sample: Patients presenting to the Emergency department with symptoms of deep vein thrombosis or pulmonary embolism.

Trial design: Prospective observational (cohort) Performance evaluation study

Target – 400

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Fiona McCurrach

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Emma Moatt

Research Project Manager

Fraser Craig

Clinical Trial Assistant

Julia Grahamslaw

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

Kayleigh Craig

Research Nurse

More EMERGE Trials

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy